U.S. markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.62-0.51 (-5.59%)
At close: 04:00PM EDT
8.29 -0.33 (-3.83%)
After hours: 07:45PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close9.13
Bid8.29 x 1300
Ask9.75 x 800
Day's Range8.26 - 9.28
52 Week Range7.40 - 18.93
Avg. Volume666,040
Market Cap461.956M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-1.80
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CARA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cara Therapeutics, Inc.
    CARA: What does Argus have to say about CARA?CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Benzinga

    Cara Therapeutics' Difelikefalin Aces Mid-Stage Study In Patients With Itchy Skin Disorder

    Cara Therapeutics Inc (NASDAQ: CARA) announced topline results from its Phase 2 proof-of-concept trial (KOMFORT) of difelikefalin for moderate-to-severe pruritus in patients with notalgia paresthetica, a nerve disorder characterized by chronic pruritus (itchy skin) of the upper to middle back. The primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour itch scale (WI-NRS) score at Week 8. Other endpoints included the ≥4-point responder analysis, itch-relate

  • GlobeNewswire

    Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

    – Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieved on the WI-NRS ≥4-point responder analysis at Week 8 (p=0.007) – – Oral difelikefalin was well tolerated with a consistent safety profile – – Conference call today at 8:30 a.m. ET – STAMFORD, Conn., June 30, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commerci

  • Insider Monkey

    10 Best CBD Stocks To Invest In

    In this article, we discuss the 10 best CBD stocks to invest in. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best CBD Stocks To Invest In. With the growing acceptance of cannabis among global consumers and their elected representatives, the CBD market has […]